Insider · CIK 0001801917
Eric Venker
coopresidentofficerceodirector
Files at ROIV (Roivant Sciences Ltd.), IMVT (Immunovant, Inc.). First filing Oct 22, 2024, latest Oct 5, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 14
$0 bought, $64M sold
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
ROIV: Roivant Sciences Ltd.
ROIVOct 9, 2026 · close 35.44
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
IMVT: Immunovant, Inc.
IMVTOct 9, 2026 · close 30.47
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | Immunovant, Inc. | $120k 3,506 shares | -1% | +109% from low-25% from high | |
| 28Weak | Roivant Sciences Ltd. | $7.3M 200,000 shares | -11% | +142% from low-13% from high | |
| 28Weak | Roivant Sciences Ltd. | $7.2M 200,000 shares | -11% | +191% from low-8% from high | |
| 35Weak | Roivant Sciences Ltd. | $26M 1,711,000 shares | -64% | +66% from low-2% from high | |
| 23Weak | Roivant Sciences Ltd. | $1.2M 100,000 shares | -6% | +29% from low-8% from high | |
| 15Weak | Roivant Sciences Ltd. | $1.2M 100,000 shares | -6% | +26% from low-10% from high | |
| 18Weak | Roivant Sciences Ltd. | $1.1M 100,000 shares | -6% | +26% from low-10% from high | |
| 58Moderate | Roivant Sciences Ltd. | $11M 1,000,000 shares | -60% | +23% from low-12% from high | |
| 18Weak | Roivant Sciences Ltd. | $1.1M 100,000 shares | -8% | +22% from low-13% from high | |
| 10Weak | Roivant Sciences Ltd. | $1.0M 100,000 shares | -8% | +11% from low-21% from high | |
| 48Moderate | Roivant Sciences Ltd. | $4.1M 354,604 shares | -42% | - | |
| 23Weak | Roivant Sciences Ltd. | $1.1M 100,000 shares | -14% | - | |
| 15Weak | Roivant Sciences Ltd. | $1.1M 100,000 shares | -14% | - | |
| 35Weak | ROIVsell Roivant Sciences Ltd. | $1.2M 100,000 shares | -14% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | IMVT Immunovant, Inc. | MOption exercise Common Stock | +92,187 | $14.46 | $1.3M | 346,467 | 7 d ago |
| Oct 1, 2026 | IMVT Immunovant, Inc. | DDisposition to issuer Common Stock | -85,886 | $33.65 | $2.9M | 260,581 | 7 d ago |
| Oct 2, 2026 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock | -3,506 | $34.11 | $120k | 257,075 | 7 d ago |
| Oct 1, 2026 | IMVT Immunovant, Inc. | MOption exercise Capped Value Appreciation Rightsderivative | -92,187 | $0.00 | $0 | 921,875 | 7 d ago |
| Sep 30, 2026 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares10b5-1 | +200,000 | $3.85 | $770k | 1,799,154 | 10 d ago |
| Sep 30, 2026 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -200,000 | $36.62 | $7.3M | 1,599,154 | 10 d ago |
| Sep 30, 2026 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -200,000 | $0.00 | $0 | 3,644,834 | 10 d ago |
| Aug 28, 2026 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares10b5-1 | +200,000 | $3.85 | $770k | 1,799,154 | 41 d ago |
| Aug 28, 2026 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -166,182 | $35.63 | $5.9M | 1,632,972 | 41 d ago |
| Aug 28, 2026 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -33,818 | $36.44 | $1.2M | 1,599,154 | 41 d ago |
| Aug 28, 2026 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -200,000 | $0.00 | $0 | 3,844,834 | 41 d ago |
| Sep 19, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares10b5-1 | +1,000,000 | $3.85 | $3.9M | 2,653,585 | Sep 23, 2025 |
| Sep 19, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -683,818 | $14.95 | $10M | 1,969,767 | Sep 23, 2025 |
| Sep 22, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares10b5-1 | +462,374 | $3.85 | $1.8M | 2,432,141 | Sep 23, 2025 |
| Sep 22, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares10b5-1 | +100,000 | $3.85 | $385k | 2,532,141 | Sep 23, 2025 |
| Sep 22, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -316,182 | $14.99 | $4.7M | 2,215,959 | Sep 23, 2025 |
| Sep 22, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -100,000 | $15.01 | $1.5M | 2,115,959 | Sep 23, 2025 |
| Sep 23, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -611,000 | $14.83 | $9.1M | 1,504,959 | Sep 23, 2025 |
| Sep 19, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,000,000 | $0.00 | $0 | 7,038,897 | Sep 23, 2025 |
| Sep 22, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -462,374 | $0.00 | $0 | 6,576,523 | Sep 23, 2025 |
| Sep 22, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 6,476,523 | Sep 23, 2025 |
| Aug 20, 2025 | ROIV Roivant Sciences Ltd. | FTax withholding Common Shares10b5-1 | -7,051 | $11.72 | $83k | 1,653,585 | Aug 22, 2025 |
| Aug 20, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares10b5-1 | +100,000 | $3.85 | $385k | 1,753,585 | Aug 22, 2025 |
| Aug 20, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -100,000 | $11.72 | $1.2M | 1,653,585 | Aug 22, 2025 |
| Aug 20, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 8,038,897 | Aug 22, 2025 |
| Jul 30, 2025 | ROIV Roivant Sciences Ltd. | AGrant or award Common Shares | +198,413 | $0.00 | $0 | 1,660,636 | Aug 1, 2025 |
| Jul 28, 2025 | IMVT Immunovant, Inc. | AGrant or award Stock Option (right to buy)derivative | +1,300,000 | $0.00 | $0 | 1,300,000 | Jul 30, 2025 |
| Jul 28, 2025 | IMVT Immunovant, Inc. | AGrant or award Stock Option (right to buy)derivative | +189,900 | $0.00 | $0 | 189,900 | Jul 30, 2025 |
| Jul 28, 2025 | IMVT Immunovant, Inc. | AGrant or award Capped Value Appreciation Rightsderivative | +1,475,000 | $0.00 | $0 | 1,475,000 | Jul 30, 2025 |
| Jul 21, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares10b5-1 | +100,000 | $3.85 | $385k | 1,562,223 | Jul 23, 2025 |
| Jul 21, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -100,000 | $11.52 | $1.2M | 1,462,223 | Jul 23, 2025 |
| Jul 21, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 8,138,897 | Jul 23, 2025 |
| Jun 20, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares10b5-1 | +100,000 | $3.85 | $385k | 1,562,223 | Jun 24, 2025 |
| Jun 20, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -100,000 | $11.45 | $1.1M | 1,462,223 | Jun 24, 2025 |
| Jun 20, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 8,238,897 | Jun 24, 2025 |
| Jun 2, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +600,000 | $3.85 | $2.3M | 1,677,197 | Jun 4, 2025 |
| Jun 2, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -433,722 | $11.07 | $4.8M | 1,243,475 | Jun 4, 2025 |
| Jun 3, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +785,026 | $3.85 | $3.0M | 2,028,501 | Jun 4, 2025 |
| Jun 3, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -566,278 | $11.22 | $6.4M | 1,462,223 | Jun 4, 2025 |
| Jun 2, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative | -600,000 | $0.00 | $0 | 9,123,923 | Jun 4, 2025 |
| Jun 3, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative | -785,026 | $0.00 | $0 | 8,338,897 | Jun 4, 2025 |
| May 20, 2025 | ROIV Roivant Sciences Ltd. | FTax withholding Common Shares10b5-1 | -39,148 | $11.04 | $432k | 1,077,197 | May 22, 2025 |
| May 20, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares10b5-1 | +100,000 | $3.85 | $385k | 1,177,197 | May 22, 2025 |
| May 20, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -100,000 | $10.95 | $1.1M | 1,077,197 | May 22, 2025 |
| May 20, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 9,723,923 | May 22, 2025 |
| Apr 20, 2025 | ROIV Roivant Sciences Ltd. | FTax withholding Common Shares10b5-1 | -10,945 | $10.15 | $111k | 1,116,345 | Apr 22, 2025 |
| Apr 21, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares10b5-1 | +100,000 | $3.85 | $385k | 1,216,345 | Apr 22, 2025 |
| Apr 21, 2025 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -100,000 | $10.22 | $1.0M | 1,116,345 | Apr 22, 2025 |
| Apr 21, 2025 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 9,823,923 | Apr 22, 2025 |
| Dec 27, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +250,000 | $3.85 | $963k | 845,580 | Dec 31, 2024 |
| Dec 27, 2024 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -176,900 | $11.82 | $2.1M | 668,680 | Dec 31, 2024 |
| Dec 30, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +250,000 | $3.85 | $963k | 918,680 | Dec 31, 2024 |
| Dec 30, 2024 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -177,704 | $11.54 | $2.1M | 740,976 | Dec 31, 2024 |
| Dec 27, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative | -250,000 | $0.00 | $0 | 11,976,234 | Dec 31, 2024 |
| Dec 30, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative | -250,000 | $0.00 | $0 | 11,726,234 | Dec 31, 2024 |
| Dec 20, 2024 | ROIV Roivant Sciences Ltd. | FTax withholding Common Shares10b5-1 | -10,945 | $11.57 | $127k | 595,580 | Dec 26, 2024 |
| Dec 20, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares10b5-1 | +100,000 | $3.85 | $385k | 695,580 | Dec 26, 2024 |
| Dec 20, 2024 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -100,000 | $11.49 | $1.1M | 595,580 | Dec 26, 2024 |
| Dec 20, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 12,226,234 | Dec 26, 2024 |
| Nov 20, 2024 | ROIV Roivant Sciences Ltd. | FTax withholding Common Shares10b5-1 | -10,945 | $11.49 | $126k | 606,525 | Nov 22, 2024 |
| Nov 20, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares10b5-1 | +100,000 | $3.85 | $385k | 706,525 | Nov 22, 2024 |
| Nov 20, 2024 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares10b5-1 | -100,000 | $11.32 | $1.1M | 606,525 | Nov 22, 2024 |
| Nov 20, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 12,326,234 | Nov 22, 2024 |
| Oct 20, 2024 | ROIV Roivant Sciences Ltd. | FTax withholding Common Shares | -10,945 | $11.92 | $130k | 617,470 | Oct 22, 2024 |
| Oct 21, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Common Shares | +100,000 | $3.85 | $385k | 717,470 | Oct 22, 2024 |
| Oct 21, 2024 | ROIV Roivant Sciences Ltd. | SOpen-market sale Common Shares | -100,000 | $11.65 | $1.2M | 617,470 | Oct 22, 2024 |
| Oct 21, 2024 | ROIV Roivant Sciences Ltd. | MOption exercise Stock Option (Right to Buy)derivative | -100,000 | $0.00 | $0 | 12,426,234 | Oct 22, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.